Skip to main content
Clinical Trials/NCT05371951
NCT05371951
Withdrawn
Not Applicable

A Pilot Evaluation of the Effect of the Erchonia® HLS™ on Individuals With Erectile Dysfunction

Erchonia Corporation1 site in 1 countryOctober 5, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Erectile Dysfunction
Sponsor
Erchonia Corporation
Locations
1
Primary Endpoint
Total Score on the International Index of Erectile Function - Erectile Function
Status
Withdrawn
Last Updated
3 years ago

Overview

Brief Summary

This study is to see if applying low-level laser light can provide improvement in erectile dysfunction

Detailed Description

The purpose of this pilot study is to determine the effectiveness of the Erchonia® HLS™, manufactured by Erchonia Corporation (the Company), in providing improvement in erectile dysfunction.

Registry
clinicaltrials.gov
Start Date
October 5, 2021
End Date
March 1, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Sponsor
Erchonia Corporation
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male between 40 and 80 years old
  • Known or suspected vasculogenic ED based on clinical history
  • In an active sexual relationship with a minimum of 2 sexual attempts per month for at least one month prior to enrollment
  • Suffering from ED for at least 6 months
  • Testosterone level between 300 - 1000ng/dL within one month prior to enrollment
  • Hgb A1C less than or equal to 8% within one month prior to enrollment
  • Total IIEF-EF scores between 8-25
  • EHS score greater than or equal to

Exclusion Criteria

  • ED due to radical prostatectomy, prior pelvic surgery, or radiation therapy to the pelvis within 12 months prior to enrollment
  • Men with known neurogenic or psychogenic ED
  • Anatomic malformations of the penis including Peyronie's disease
  • Testosterone greater than 300ng/dL or 1000ng/dL
  • Hgb A1C greater than 8%
  • International Normalized Ratio greater than 2.5, and men on any blood thinners other than 81mg aspirin
  • Active testicular or prostate cancer

Outcomes

Primary Outcomes

Total Score on the International Index of Erectile Function - Erectile Function

Time Frame: 6 week

The International Index of Erectile Function - Erectile Function ( domain score is a patient questionnaire (six questions) used to measure various aspects of erectile performance and assess disease severity in efficacy trials concerning ED. The International Index of Erectile Function - Erectile Function has a minimum score of 0 and max of 30, higher scores mean a better outcome

Secondary Outcomes

  • Total Erection Hardness Score(6 week)

Study Sites (1)

Loading locations...

Similar Trials